Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 8 | 2014 | 794 | 0.540 |
Why?
|
| Poliovirus Vaccines | 1 | 2012 | 1 | 0.450 |
Why?
|
| Chemokine CXCL10 | 1 | 2012 | 37 | 0.430 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 56 | 0.430 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 70 | 0.420 |
Why?
|
| Hela Cells | 1 | 2012 | 344 | 0.410 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2010 | 29 | 0.390 |
Why?
|
| Universities | 2 | 2012 | 363 | 0.380 |
Why?
|
| Peptides | 1 | 2012 | 308 | 0.350 |
Why?
|
| Peptide Fragments | 1 | 2010 | 298 | 0.330 |
Why?
|
| Biomedical Research | 1 | 2012 | 371 | 0.320 |
Why?
|
| Antineoplastic Agents | 2 | 2012 | 756 | 0.240 |
Why?
|
| ral GTP-Binding Proteins | 1 | 2002 | 8 | 0.220 |
Why?
|
| Synaptic Vesicles | 1 | 2002 | 29 | 0.210 |
Why?
|
| Crotonates | 1 | 2021 | 1 | 0.200 |
Why?
|
| Hydroxybutyrates | 1 | 2021 | 2 | 0.200 |
Why?
|
| Toluidines | 1 | 2021 | 3 | 0.200 |
Why?
|
| Paraparesis, Tropical Spastic | 1 | 2021 | 12 | 0.200 |
Why?
|
| Nitriles | 1 | 2021 | 66 | 0.200 |
Why?
|
| Cell Movement | 3 | 2012 | 545 | 0.190 |
Why?
|
| Quercetin | 2 | 2012 | 41 | 0.190 |
Why?
|
| Adenocarcinoma | 3 | 2010 | 239 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 224 | 0.180 |
Why?
|
| Prostate | 2 | 2010 | 136 | 0.180 |
Why?
|
| DNA Damage | 2 | 2012 | 341 | 0.170 |
Why?
|
| Cell Proliferation | 6 | 2021 | 1149 | 0.170 |
Why?
|
| MicroRNAs | 2 | 2014 | 386 | 0.150 |
Why?
|
| Cell Line, Tumor | 6 | 2014 | 2128 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 984 | 0.140 |
Why?
|
| Alabama | 2 | 2012 | 46 | 0.140 |
Why?
|
| Humans | 15 | 2021 | 34853 | 0.130 |
Why?
|
| Protein Binding | 2 | 2012 | 913 | 0.130 |
Why?
|
| Interinstitutional Relations | 2 | 2013 | 35 | 0.130 |
Why?
|
| Enzyme Activation | 2 | 2012 | 423 | 0.120 |
Why?
|
| Regional Health Planning | 1 | 2013 | 14 | 0.120 |
Why?
|
| Neoplasms | 3 | 2013 | 1033 | 0.120 |
Why?
|
| Minority Health | 1 | 2013 | 81 | 0.120 |
Why?
|
| Poliomyelitis | 1 | 2012 | 7 | 0.110 |
Why?
|
| Receptors, CXCR3 | 1 | 2012 | 30 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2012 | 110 | 0.110 |
Why?
|
| Cell Cycle | 2 | 2012 | 309 | 0.110 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2012 | 70 | 0.110 |
Why?
|
| Antibodies, Neutralizing | 1 | 2012 | 102 | 0.100 |
Why?
|
| Cyclic AMP | 1 | 2012 | 125 | 0.100 |
Why?
|
| Ruta | 1 | 2011 | 3 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 2012 | 351 | 0.100 |
Why?
|
| Coculture Techniques | 1 | 2010 | 96 | 0.090 |
Why?
|
| Ethics, Research | 1 | 2010 | 17 | 0.090 |
Why?
|
| Health Status Disparities | 2 | 2013 | 583 | 0.090 |
Why?
|
| Nocodazole | 1 | 2010 | 9 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 178 | 0.090 |
Why?
|
| Tubulin Modulators | 1 | 2010 | 16 | 0.090 |
Why?
|
| Paclitaxel | 1 | 2010 | 48 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 1124 | 0.090 |
Why?
|
| Colorectal Neoplasms | 2 | 2012 | 413 | 0.090 |
Why?
|
| Male | 9 | 2021 | 18870 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 531 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 1490 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2012 | 296 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 446 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 245 | 0.090 |
Why?
|
| Communication | 1 | 2010 | 170 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 182 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 205 | 0.080 |
Why?
|
| Models, Molecular | 1 | 2012 | 751 | 0.080 |
Why?
|
| Antioxidants | 1 | 2012 | 386 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2010 | 107 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2012 | 781 | 0.080 |
Why?
|
| Plant Extracts | 1 | 2011 | 250 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2012 | 653 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2010 | 366 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2021 | 1152 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2012 | 1802 | 0.070 |
Why?
|
| Apoptosis | 2 | 2012 | 1317 | 0.070 |
Why?
|
| Cell Line | 2 | 2010 | 1289 | 0.060 |
Why?
|
| Cell Survival | 2 | 2021 | 818 | 0.060 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 2002 | 2 | 0.050 |
Why?
|
| Genes, Dominant | 1 | 2002 | 18 | 0.050 |
Why?
|
| Synaptosomes | 1 | 2002 | 21 | 0.050 |
Why?
|
| Exocytosis | 1 | 2002 | 45 | 0.050 |
Why?
|
| Macromolecular Substances | 1 | 2002 | 86 | 0.050 |
Why?
|
| Vesicular Transport Proteins | 1 | 2002 | 40 | 0.050 |
Why?
|
| Brain Chemistry | 1 | 2002 | 134 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2012 | 21 | 0.050 |
Why?
|
| Gene Products, tax | 1 | 2021 | 4 | 0.050 |
Why?
|
| HTLV-I Infections | 1 | 2021 | 31 | 0.050 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2021 | 33 | 0.050 |
Why?
|
| Protein Kinase C | 1 | 2002 | 110 | 0.050 |
Why?
|
| Cyclin B1 | 2 | 2012 | 16 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 247 | 0.050 |
Why?
|
| Synaptic Transmission | 1 | 2002 | 141 | 0.050 |
Why?
|
| Glutamic Acid | 1 | 2002 | 115 | 0.050 |
Why?
|
| Middle Aged | 4 | 2021 | 9642 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 84 | 0.050 |
Why?
|
| Aged | 3 | 2021 | 6448 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2012 | 392 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2002 | 608 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2002 | 287 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2002 | 338 | 0.040 |
Why?
|
| Calcium | 1 | 2002 | 445 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2002 | 878 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2012 | 834 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2012 | 200 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2002 | 486 | 0.040 |
Why?
|
| Mice | 2 | 2010 | 5668 | 0.040 |
Why?
|
| Brain | 1 | 2002 | 1268 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2013 | 48 | 0.030 |
Why?
|
| Community Networks | 1 | 2013 | 98 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 63 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2013 | 159 | 0.030 |
Why?
|
| Epidermal Growth Factor | 1 | 2012 | 63 | 0.030 |
Why?
|
| Subcellular Fractions | 1 | 2012 | 72 | 0.030 |
Why?
|
| Cadherins | 1 | 2012 | 82 | 0.030 |
Why?
|
| Etoposide | 1 | 2012 | 21 | 0.030 |
Why?
|
| Camptothecin | 1 | 2012 | 20 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2012 | 32 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2012 | 32 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 54 | 0.030 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2012 | 72 | 0.030 |
Why?
|
| Adult | 2 | 2021 | 11034 | 0.030 |
Why?
|
| Protein Transport | 1 | 2012 | 286 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2012 | 171 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 5 | 0.020 |
Why?
|
| Animals | 2 | 2010 | 14307 | 0.020 |
Why?
|
| Morals | 1 | 2010 | 12 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 86 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 600 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 143 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 185 | 0.020 |
Why?
|
| Plants, Medicinal | 1 | 2011 | 54 | 0.020 |
Why?
|
| Androgens | 1 | 2010 | 87 | 0.020 |
Why?
|
| Food-Drug Interactions | 1 | 2010 | 5 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2011 | 194 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 580 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2010 | 55 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 136 | 0.020 |
Why?
|
| G2 Phase | 1 | 2010 | 25 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2011 | 480 | 0.020 |
Why?
|
| Tubulin | 1 | 2010 | 80 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2013 | 1352 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 209 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 209 | 0.020 |
Why?
|
| Microtubules | 1 | 2010 | 113 | 0.020 |
Why?
|
| Schools, Medical | 1 | 2010 | 192 | 0.020 |
Why?
|
| Female | 2 | 2021 | 19873 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 2333 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 1681 | 0.020 |
Why?
|
| Young Adult | 1 | 2012 | 4012 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1426 | 0.010 |
Why?
|